BTG3 and rheumatoid arthritis: The clinical safety was parallel to immunological safety, as inferred by slight, not significant, ANA titer modifications, without new autoantibody appearance, thus confirming the original result of Blank et al. in inflammatory arthritis after BNT162b2 vaccine [44] and our previous observations in RA patients and healthy subjects after common vaccines [48,53].